Literature DB >> 23179792

An unusual BRCA mutation distribution in a high risk cancer genetics clinic.

Anna C Nelson-Moseke1, Joanne M Jeter, Haiyan Cui, Denise J Roe, Setsuko K Chambers, Christina M Laukaitis.   

Abstract

The Database of Individuals at High Risk for Breast, Ovarian, or Other Hereditary Cancers at the Arizona Cancer Center in Tucson, Arizona assesses cancer risk factors and outcomes in patients with a family history of cancer or a known genetic mutation. We analyzed the subset of clinic probands who carry deleterious BRCA gene mutations to identify factors that could explain why mutations in BRCA2 outnumber those in BRCA1. Medical, family, social, ethnic and genetic mutation histories were collected from consenting patients' electronic medical records. Differences between BRCA1 and BRCA2 probands from this database were analyzed for statistical significance and compared to published analyses. A significantly higher proportion of our clinic probands carry mutations in BRCA2 than BRCA1, compared with previous reports of mutation prevalence. This also holds true for the Hispanic sub-group. Probands with BRCA2 mutations were significantly more likely than their BRCA1 counterparts to present to the high risk clinic without a diagnosis of cancer. Other differences between the groups were not significant. Six previously unreported BRCA2 mutations appear in our clinic population. The increased proportion of probands carrying deleterious BRCA2 mutations is likely multifactorial, but may reflect aspects of Southern Arizona's unique ethnic heritage.

Entities:  

Mesh:

Year:  2013        PMID: 23179792      PMCID: PMC3563940          DOI: 10.1007/s10689-012-9581-z

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  17 in total

1.  Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Authors:  Jaya M Satagopan; Jeff Boyd; Noah D Kauff; Mark Robson; Lauren Scheuer; Steven Narod; Kenneth Offit
Journal:  Clin Cancer Res       Date:  2002-12       Impact factor: 12.531

2.  Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.

Authors:  Kathleen E Malone; Janet R Daling; David R Doody; Li Hsu; Leslie Bernstein; Ralph J Coates; Polly A Marchbanks; Michael S Simon; Jill A McDonald; Sandra A Norman; Brian L Strom; Ronald T Burkman; Giske Ursin; Dennis Deapen; Linda K Weiss; Suzanne Folger; Jennifer J Madeoy; Danielle M Friedrichsen; Nicola M Suter; Mariela C Humphrey; Robert Spirtas; Elaine A Ostrander
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

Review 3.  Hereditary cancer predisposition syndromes.

Authors:  Judy E Garber; Kenneth Offit
Journal:  J Clin Oncol       Date:  2005-01-10       Impact factor: 44.544

4.  Prevalence of BRCA mutations and founder effect in high-risk Hispanic families.

Authors:  Jeffrey N Weitzel; Veronica Lagos; Kathleen R Blazer; Rebecca Nelson; Charité Ricker; Josef Herzog; Colleen McGuire; Susan Neuhausen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-07       Impact factor: 4.254

Review 5.  The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.

Authors:  Therese B Bevers
Journal:  J Natl Compr Canc Netw       Date:  2007-09       Impact factor: 11.908

6.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Authors:  B Fisher; J P Costantino; D L Wickerham; C K Redmond; M Kavanah; W M Cronin; V Vogel; A Robidoux; N Dimitrov; J Atkins; M Daly; S Wieand; E Tan-Chiu; L Ford; N Wolmark
Journal:  J Natl Cancer Inst       Date:  1998-09-16       Impact factor: 13.506

Review 7.  Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.

Authors:  Noah D Kauff; Richard R Barakat
Journal:  J Clin Oncol       Date:  2007-07-10       Impact factor: 44.544

Review 8.  Hereditary ovarian cancer.

Authors:  Antonio Russo; Valentina Calò; Loredana Bruno; Sergio Rizzo; Viviana Bazan; Gaetana Di Fede
Journal:  Crit Rev Oncol Hematol       Date:  2008-07-24       Impact factor: 6.312

9.  BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.

Authors:  Michael J Hall; Julia E Reid; Lynn A Burbidge; Dmitry Pruss; Amie M Deffenbaugh; Cynthia Frye; Richard J Wenstrup; Brian E Ward; Thomas A Scholl; Walter W Noll
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

10.  Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations.

Authors:  A Moran; C O'Hara; S Khan; L Shack; E Woodward; E R Maher; F Lalloo; D G R Evans
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

View more
  2 in total

1.  Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.

Authors:  Christine Gruessner; Angelika Gruessner; Katherine Glaser; Nisreen AbuShahin; Yi Zhou; Cynthia Laughren; Heather Wright; Samantha Pinkerton; Xiaofang Yi; Jha'nae Stoffer; Masoud Azodi; Wenxin Zheng; Setsuko K Chambers
Journal:  Cancer Prev Res (Phila)       Date:  2014-06-20

2.  Biomarkers and endosalpingiosis in the ovarian and tubal microenvironment of women at high-risk for pelvic serous carcinoma.

Authors:  Christine Gruessner; Angelika Gruessner; Katherine Glaser; Nisreen Abushahin; Cynthia Laughren; Wenxin Zheng; Setsuko K Chambers
Journal:  Am J Cancer Res       Date:  2014-01-15       Impact factor: 6.166

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.